Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group phase III trial

Blood

Volumn 88, Issue 7, 1996, Pages 2699-2706

  Liu, Pocheng ^b   Leong, Traci ^b   Quam, Lynn ^b   Billadeau, Daniel ^b   Kay, Neil E ^b   Greipp, Philip ^b   Kyle, Robert A ^b   Oken, Martin M ^b   Van Ness, Brian ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; PREDNISONE;

ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0029819604     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2699.bloodjournal8872699     Document Type: Article

References (38)

1. Kyle RA: Diagnostic criteria of multiple myeloma. [Review]. Hematol Oncol Clin North Am 6:347, 1992
2. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A: Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 81:2708, 1993
3. Corradini P, Ladetto M, Inghirami G, Boccadoro M, Pileri A: N- and K-ras oncogenes in plasma cell dyscrasias. [Review]. Leuk Lymphoma 15:17, 1994
4. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, Pileri A, Dalla-Favera R: Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758, 1994
5. Imamura N, Kuramoto A, Ishihara H, Shimizu S: Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia. Am J Hematol 43:151, 1993
6. Kadam P, Steele P, Li YQ, Preisler H: Analysis of the c-myc and N-ras genes in acute myelogenous leukemia cells which manifest the constitutive expression of the c-myc gene. Anticancer Res 13:747, 1993
7. Matozaki S, Nakagawa T, Nakao Y, Fujita T: RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J Med Sci 37:35, 1991
8. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539, 1992
9. Tanaka K, Takechi M, Asaoku H, Dohy H, Kamada N: A high frequency of N-RAS oncogene mutations in multiple myeloma. Int J Hematol 56:119, 1992
10. Skopelitou A, Hadjiyannakis M, Tsenga A, Theocharis S, Alexopoulou V, Kittas C, Agnantis N: Expression of C-myc p62 oncoprotein in multiple myeloma: An immunohistochemical study of 180 cases. Anticancer Res 13:1091, 1993
11. Pettersson M, Jernberg WH, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K: Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79:495, 1992
12. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB: Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer. Oncogene 4:923, 1989
13. Bos JL: Ras oncogenes in human cancer: A review [published erratum appears in Cancer Res 50:1352, 1990]. [Review]. Cancer Res 49:4682, 1989
14. Toksoz D, Farr CJ, Marshall CJ: Ras genes and acute myeloid leukaemia. [Review]. Br J Haematol 71:1, 1989
15. Ahuja HG, Foti A, Bar EM, Cline MJ: The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 75:1684, 1990
16. Bos JL, Verlaan-de VM, van der Eb AJ, Janssen JW, Delwel R, Lowenberg B, Colly LP: Mutations in N-ras predominate in acute myeloid leukemia. Blood 69:1237, 1987
17. Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla FR: Ras oncogene mutation in multiple myeloma. J Exp Med 170:1715, 1989
18. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP: Oncogenes in multiple myeloma: Point mutation of N-ras. Oncogene 5:1659, 1990
19. Billadeau D, Liu P, Nisha S, LeBien TW, Jelinek DF, Van Ness B: Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6 dependent myeloma cell line ANBL6 (submitted)
20. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B: Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 55:3640, 1995
21. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B: Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 78:3021, 1991
22. Neri A, Knowles DM, Greco A, McCormick F, Dalla FR: Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85:9268, 1988
23. Verlaan-de VM, Bogaard ME, van den Elst H, van Boom JH, van der Eb Aj, Bos JL: A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. Gene 50:313, 1986
24. Todd AV, Ireland CM, Hand HJ: Allele-specific enrichment: A method for the detection of low level N-ras gene mutations in acute myeloid leukemia. Leukemia 5:160, 1991
25. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874, 1989
26. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5:1037, 1990
27. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525, 1988
28. Bergsagel PL, Belch AR, Pilarski LM: The blood B cells and bone marrow plasma cells in a patient with multiple myeloma includes cells with the same N-ras mutation. Blood 84:524a, 1994 (suppl)
29. Kyle RA: "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 68:26, 1993
30. Bos JL: Ras oncogenes in hematopoietic malignancies. [Review]. Hematol Pathol 2:55, 1988
31. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83, 1988
32. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
33. Satoh T, Nakafuku M, Miyajima A, Kaziro Y: Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc Nail Acad Sci USA 88:3314, 1991
34. Muszynski KW, Ruscetti FW, Heidecker G, Rapp U, Troppmair J, Gooya JM, Keller JR: Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells. J Exp Med 181:2189, 1995
35. Sato N, Sakamaki K, Terada N, Arai K, Miyajima A: Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 12:4181, 1993
36. Quelle FW, Sato N, Witthuhn BA, Inborn RC, Eder M, Miyajima A, Griffin JD, Ihle JN: JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol 14:4335, 1994
37. de la Rubia J, Bonanad S, Palau J, Sanz GF, Sanz MA: Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant 14:475, 1994
38. Brown RD, Pope B, Luo XF, Gibson J, Joshua D: The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma 16:147, 1994